Augmentin Uses

• Augmentin indications
• Uses of Augmentin in details
• Augmentin description
• Augmentin dosage
• Augmentin interactions
• Augmentin side effects
• Augmentin contraindications

What is Augmentin?

Augmentin is a penicillin antibiotic.

Augmentin contains a combination of Augmentin and Clavulanate potassium (Augmentin). Augmentin is an antibiotic in a group of drugs called penicillins. Augmentin fights bacteria in the body.

Clavulanate potassium (Augmentin) is a form of clavulanic acid, which is similar to penicillin. Clavulanate potassium (Augmentin) fights bacteria that is often resistant to penicillins and other antibiotics.

Augmentin is used to treat many different infections caused by bacteria, such as sinusitis, pneumonia, ear infections, bronchitis, urinary tract infections, and infections of the skin.

Augmentin may also be used for purposes not listed in this medication guide.

Augmentin indications

Augmentin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below:

Lower Respiratory Tract Infections

− caused by β-lactamase−producing strains of H. influenzae and M. catarrhalis.

Otitis Media

− caused by β-lactamase−producing strains of H. influenzae and M. catarrhalis.

Sinusitis

− caused by β-lactamase−producing strains of H. influenzae and M. catarrhalis.

Skin and Skin Structure Infections

− caused by β-lactamase−producing strains of S. aureus, E. coli, and Klebsiella spp.

Urinary Tract Infections

− caused by β-lactamase−producing strains of E. coli, Klebsiella spp., and Enterobacter spp.

While Augmentin is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with Augmentin due to its Augmentin content; therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase−producing organisms susceptible to Augmentin should not require the addition of another antibiotic. Because Augmentin has greater in vitro activity against S. pneumoniae than does ampicillin or penicillin, the majority of S. pneumoniae strains with intermediate susceptibility to ampicillin or penicillin are fully susceptible to Augmentin and Augmentin.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Augmentin and other antibacterial drugs, Augmentin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Bacteriological studies, to determine the causative organisms and their susceptibility to Augmentin, should be performed together with any indicated surgical procedures.

How should I use Augmentin?

Use Augmentin as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Augmentin by mouth at the start of a meal to decrease the chance of stomach upset.
• Swallow Augmentin whole. Do not break, crush, or chew before swallowing. If you have difficulty swallowing the whole tablet, this tablet may be broken in half.
• To clear up your infection completely, take Augmentin for the full course of treatment. Keep taking it even if you feel better in a few days.
• If you miss a dose of Augmentin, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Augmentin.

Uses of Augmentin in details

Use: Labeled Indications

Otitis media, acute:

Immediate-release tablets, chewable tablets, oral suspension (400/57 mg per 5 mL, 250/62.5 mg per 5 mL, 200/28.5 mg per 5 mL, and 125/31.25 mg per 5 mL only): Treatment of otitis media caused by beta-lactamase-producing strains of H. influenzae and M. catarrhalis.

Oral suspension (600/42.9 mg per 5 mL concentration): Treatment of acute otitis media, recurrent or persistent, caused by S. pneumoniae (penicillin MIC = 2 mcg/mL or less), H. influenzae (including beta-lactamase-producing strains), and M. catarrhalis (including beta-lactamase-producing strains) in pediatric patients with a history of antibiotic exposure for acute otitis media in the preceding 3 months and who are either 2 years or younger or attend day care.

Pneumonia:

Extended-release tablets only: Treatment of patients with community-acquired pneumonia (CAP) caused by confirmed or suspected beta-lactamase-producing pathogens (ie, Haemophilus influenzae, Moraxella catarrhalis, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus) and Streptococcus pneumoniae with reduced susceptibility to penicillin (penicillin minimum inhibitory concentration [MIC] = 2 mcg/mL).

Limitations of use: Augmentin is not indicated for the treatment of infections caused by S. pneumoniae with penicillin MIC of 4 mcg/mL or greater (limited data).

Immediate-release tablets, chewable tablets, oral suspension (400/57 mg per 5 mL, 250/62.5 mg per 5 mL, 200/28.5 mg per 5 mL, and 125/31.25 mg per 5 mL only): Treatment of lower respiratory tract infection caused by beta-lactamase-producing strains of H. influenzae and M. catarrhalis.

Rhinosinusitis, acute bacterial:

Extended-release tablets: Treatment of patients with acute bacterial sinusitis caused by confirmed or suspected beta-lactamase-producing pathogens (ie, H. influenzae, M. catarrhalis, H. parainfluenzae, K. pneumoniae, methicillin-susceptible S. aureus) and S. pneumoniae with reduced susceptibility to penicillin (penicillin MIC = 2 mcg/mL).

Limitations of use: Augmentin is not indicated for the treatment of infections caused by S. pneumoniae with penicillin MIC of 4 mcg/mL or greater (limited data).

Immediate-release tablets, chewable tablets, oral suspension (400/57 mg per 5 mL, 250/62.5 mg per 5 mL, 200/28.5 mg per 5 mL, and 125/31.25 mg per 5 mL only): Treatment of sinusitis caused by beta-lactamase-producing strains of H. influenzae and M. catarrhalis.

Skin and skin structure infections: Immediate-release tablets, chewable tablets, oral suspension (400/57 mg per 5 mL, 250/62.5 mg per 5 mL, 200/28.5 mg per 5 mL, and 125/31.25 mg per 5 mL only): Treatment of skin and skin structure infections caused by beta-lactamase-producing strains of S. aureus, Escherichia coli, and Klebsiella spp.

Urinary tract infections: Immediate-release tablets, chewable tablets, oral suspension (400/57 mg per 5 mL, 250/62.5 mg per 5 mL, 200/28.5 mg per 5 mL, and 125/31.25 mg per 5 mL only): Treatment of urinary tract infections caused by beta-lactamase-producing strains of E. coli, Klebsiella spp, and Enterobacter spp.

Off Label Uses

Bite wound, prophylaxis or treatment (animal or human bite)

Based on the Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and management of skin and soft tissue infections (SSTIs), Augmentin/clavulanate is an effective and recommended treatment or prophylaxis of animal or human bite wounds.

Bronchiectasis, acute exacerbation

Clinical experience suggests the utility of Augmentin and clavulanate for the treatment of acute exacerbations of bronchiectasis.

Streptococcus (group A), chronic carriage

Based on the IDSA clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis, Augmentin and clavulanate is effective and recommended for eradication of group A streptococci in chronic carriers.

Augmentin description

Tablet: Co-amoxiclav 375 mg Tablet: Each tablet contains 250 mg Augmentin and 125 mg clavulanic acid.

Co-amoxiclav 625 mg Tablet: Each tablet contains 500 mg Augmentin and 125 mg clavulanic acid.

Co-amoxiclav 1 g Tablet: Each tablet contains 875 mg Augmentin and 125 mg clavulanic acid.

Oral Suspension:

Co-amoxiclav 156.25 mg/5 mL Powder for Suspension: When reconstituted, each 5 mL contains 125 mg Augmentin and 31.25 mg clavulanic acid.

Co-amoxiclav 312.5 mg/5 mL Powder for Suspension: When reconstituted, each 5 mL contains 250 mg Augmentin and 62.5 mg clavulanic acid.

Co-amoxiclav 228.5 mg/5 mL Powder for Suspension: When reconstituted, each 5 mL contains 200 mg Augmentin and 28.5 mg clavulanic acid.

Co-amoxiclav 457 mg/5 mL Powder for Suspension: When reconstituted, each 5 mL contains 400 mg Augmentin and 57 mg clavulanic acid.

Infant Drops: Co-amoxiclav 50 mg/12.5 mg per mL Powder for suspension (Infant Drops): Bottle of Dry powder for reconstitution in water, at time of dispensing, to form an oral sugar-free suspension.

Each mL of the reconstituted suspension contains 50 mg Augmentin as trihydrate and 12.5 mg clavulanic acid as potassium salt.

Injection: Co-Amoxiclav (Augmentin 600) 500 mg/100 mg Injection: Each vial contains 500 mg Augmentin and 100 mg potassium clavulanate for reconstitution as an intravenous injection or infusion.

Co-Amoxiclav (Augmentin 1.2) 1 g/200 mg Injection: Each vial contains 1 g Augmentin and 200 mg potassium clavulanate for reconstitution as an intravenous injection or infusion.

Augmentin dosage

Since both the 250-mg and 500-mg tablets of Augmentin contain the same amount of clavulanic acid (125 mg, as the potassium salt), two 250-mg tablets of Augmentin are not equivalent to one 500-mg tablet of Augmentin; therefore, two 250-mg tablets of Augmentin should not be substituted for one 500-mg tablet of Augmentin.

Dosage:

Adults:

The usual adult dose is one 500-mg tablet of Augmentin every 12 hours or one 250-mg tablet of Augmentin every 8 hours. For more severe infections and infections of the respiratory tract, the dose should be one 875-mg tablet of Augmentin every 12 hours or one 500-mg tablet of Augmentin every 8 hours.

Patients with impaired renal function do not generally require a reduction in dose unless the impairment is severe. Severely impaired patients with a glomerular filtration rate of <30 mL/min. should not receive the 875-mg tablet. Patients with a glomerular filtration rate of 10 to 30 mL/min. should receive 500 mg or 250 mg every 12 hours, depending on the severity of the infection. Patients with a less than 10 mL/min. glomerular filtration rate should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection.

Hemodialysis patients should receive 500 mg or 250 mg every 24 hours, depending on severity of the infection. They should receive an additional dose both during and at the end of dialysis.

Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals.

Pediatric Patients:

Pediatric patients weighing 40 kg or more should be dosed according to the adult recommendations.

Due to the different Augmentin to clavulanic acid ratios in the 250-mg tablet of Augmentin (250/125) versus the 250-mg chewable tablet of Augmentin (250/62.5), the 250-mg tablet of Augmentin should not be used until the pediatric patient weighs at least 40 kg or more.

Administration:

Augmentin may be taken without regard to meals; however, absorption of Clavulanate potassium (Augmentin) is enhanced when Augmentin is administered at the start of a meal. To minimize the potential for gastrointestinal intolerance, Augmentin should be taken at the start of a meal.

Augmentin interactions

See also:
What other drugs will affect Augmentin?

Concomitant use of probenecid is not recommended. Probenecid decreases the renal tubular secretion of Augmentin. Concomitant use with Augmentin may result in increased and prolonged blood levels of Augmentin but not of clavulanate.

Concomitant use of allopurinol during treatment with Augmentin can increase the likelihood of allergic skin reactions. There are no data on the concomitant use of Augmentin and allopurinol.

In common with other antibiotics, Augmentin may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.

The presence of clavulanic acid in Augmentin may cause a non-specific binding of IgG and albumin by red cell membranes leading to a false positive Coombs test.

In the literature there are rare cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of Augmentin. If co-administration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of Augmentin.

In patients receiving mycophenolate mofetil, reduction in pre-dose concentration of the active metabolite mycophenolic acid of approximately 50% has been reported following commencement of oral Augmentin plus clavulanic acid. The change in pre-dose level may not accurately represent changes in overall MPA exposure.

Incompatibilities: Tablet/Suspension: None Known.

Injection: Augmentin IV should not be mixed with blood products, other proteinaceous fluids eg, protein hydrolysates or with intravenous lipid emulsions.

If Augmentin is prescribed concurrently with an aminoglycoside, the antibiotics should not be mixed in the syringe, intravenous fluid container or giving set because loss of activity of the aminoglycoside can occur under these conditions.

Augmentin side effects

See also:
What are the possible side effects of Augmentin?

The following are discussed in more detail in other sections of the labeling:

• Anaphylactic reactions
• Hepatic Dysfunction
• CDAD

Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The most frequently reported adverse reactions were diarrhea/loose stools (9%), nausea (3%), skin rashes and urticaria (3%), vomiting (1%) and vaginitis (1%). Less than 3% of patients discontinued therapy because of drug related adverse reactions. The overall incidence of adverse reactions, and in particular diarrhea, increased with the higher recommended dose. Other less frequently reported adverse reactions (<1%) include: Abdominal discomfort, flatulence, and headache.

In pediatric patients (aged 2 months to 12 years), 1 US/Canadian clinical trial was conducted which compared 45/6.4 mg/kg/day (divided every 12 hours) of AUGMENTIN for 10 days versus 40/10 mg/kg/day (divided every 8 hours) of AUGMENTIN for 10 days in the treatment of acute otitis media. A total of 575 patients were enrolled, and only the suspension formulations were used in this trial. Overall, the adverse reactions seen were comparable to that noted above; however, there were differences in the rates of diarrhea, skin rashes/urticaria, and diaper area rashes.

Postmarketing Experience

In addition to adverse reactions reported from clinical trials, the following have been identified during postmarketing use of AUGMENTIN. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to AUGMENTIN.

Gastrointestinal

Indigestion, gastritis, stomatitis, glossitis, black “hairy” tongue, mucocutaneous candidiasis, enterocolitis, and hemorrhagic/pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment.

Hypersensitivity Reactions

Pruritus, angioedema, serum sickness–like reactions (urticaria or skin rash accompanied by arthritis, arthralgia, myalgia, and frequently fever), erythema multiforme, Stevens Johnson syndrome, acute generalized exanthematouspustulosis, hypersensitivity vasculitis, and cases of exfoliative dermatitis (including toxic epidermal necrolysis) have been reported.

Liver

Hepatic dysfunction, including hepatitis and cholestatic jaundice, increases in serum transaminases (AST and/or ALT), serum bilirubin, and/or alkaline phosphatase, has been reported with AUGMENTIN. It has been reported more commonly in the elderly, in males, or in patients on prolonged treatment. The histologic findings on liver biopsy have consisted of predominantly cholestatic, treatment. The histologic findings on liver biopsy have consisted of predominantly cholestatic, hepatocellular, or mixed cholestatic hepatocellular changes. The onset of signs/symptoms of hepatic dysfunction may occur during or several weeks after therapy has been discontinued. The hepatic dysfunction, which may be severe, is usually reversible. Deaths have been reported.

Renal

Interstitial nephritis, hematuria, and crystalluria have been reported.

Hemic And Lymphatic Systems

Anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosishave been reported. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. Thrombocytosis was noted in less than 1% of the patients treated with AUGMENTIN. There have been reports of increased prothrombin time in patients receiving AUGMENTIN and anticoagulant therapy concomitantly.

Central Nervous System

Agitation, anxiety, behavioral changes, confusion, convulsions, dizziness, insomnia, and reversible hyperactivity have been reported.

Miscellaneous

Tooth discoloration (brown, yellow, or gray staining) has been reported. Most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.

Augmentin contraindications

See also:
What is the most important information I should know about Augmentin?

4.1 Serious Hypersensitivity Reactions

Augmentin is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to Augmentin, clavulanate or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins).

4.2 Cholestatic Jaundice/Hepatic Dysfunction

Augmentin is contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with treatment with Augmentin/Clavulanate potassium (Augmentin).

4.3 Renal Impairment

Augmentin is contraindicated in patients with severe renal impairment (creatinine clearance < 30 mL/min) and in hemodialysis patients.

Active ingredient matches for Augmentin:

Amoxicillin/clavulanate potassium in Australia, Austria, Bahrain, Bangladesh, Belgium, Bosnia & Herzegowina, Bulgaria, Costa Rica, Croatia (Hrvatska), Czech Republic, Dominican Republic, Ecuador, El Salvador, Estonia, Ethiopia, Finland, France, Georgia, Greece, Guatemala, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Ireland, Israel, Italy, Kuwait, Latvia, Lithuania, Luxembourg, Malaysia, Malta, Mexico, Myanmar, New Zealand, Nicaragua, Oman, Panama, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russian Federation, Serbia, Singapore, Slovakia, Slovenia, South Africa, Sri Lanka, Switzerland, Taiwan, Thailand, Tunisia, United Arab Emirates, United Kingdom, United States, Venezuela.

Alendronic Acid/Amoxicillin/Clavulanic Acid in Greece.

Amoxicillin in Latvia.

Amoxicillin sodium or amoxicillin trihydrate/potassium clavulanate in Hungary.

Amoxicillin trihydrate/clavulanate K in Singapore.

Amoxicillin trihydrate/potassium clavulanate in Australia, France, United States, Italy, United Kingdom, Ireland, Netherlands, South Africa, Switzerland, Belgium, Austria, Portugal, Brazil, Hong Kong, Mexico, Israel, Thailand, Singapore, Finland, New Zealand, Greece, Chile, Czech Republic, Russia, Venezuela, Turkey, Poland, Philippines, Indonesia, Malaysia, India.

Amoxicillin/Clavulanic Acid in Australia, Austria, Bahrain, Belgium, Bosnia & Herzegowina, Bulgaria, Chile, China, Croatia (Hrvatska), Czech Republic, Ecuador, Estonia, Ethiopia, Finland, France, Georgia, Hong Kong, Hungary, Iceland, India, Indonesia, Ireland, Israel, Italy, Japan, Lithuania, Luxembourg, Malaysia, Malta, Mexico, Myanmar, Netherlands, New Zealand, Oman, Pakistan, Peru, Philippines, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, Slovenia, South Africa, Switzerland, Taiwan, Thailand, Tunisia, United Kingdom, United States, Venezuela, Vietnam.

Amoxycillin in Hongkong.

Amoxicillin Na/amoxicillin trihydrate/Co-amoxiclav: Clavulanate K in Malaysia.

Amoxicillin and enzyme inhibitor in Romania.

Amoxicillin/AMOXICILLIN 250mg/clavulanate/clavulanate potassium/CLAVULANATE POTASSIUM 125mg/Clavulanic Acid/Potassium Clavulanate

Clavulanate K/clavulanic acid/Co-amoxiclav in Philippines.

Unit description / dosage (Manufacturer)	Price, USD
Injectable; Injection; Amoxicillin Trihydrate 1000 mg; Clavulanic Acid / Clavulanate Potassium 200 mg
Injectable; Injection; Amoxicillin Trihydrate 2000 mg; Clavulanic Acid / Clavulanate Potassium 200 mg
Injectable; Injection; Amoxicillin Trihydrate 500 mg; Clavulanic Acid / Clavulanate Potassium 100 mg
Injectable; Injection; Amoxicillin Trihydrate 500 mg; Clavulanic Acid / Clavulanate Potassium 50 mg
Injectable; Subcutaneous; Amoxicillin Sodium 1 g; Clavulanic Acid / Clavulanate Potassium 100 mg
Injectable; Subcutaneous; Amoxicillin Sodium 2 g; Clavulanic Acid / Clavulanate Potassium 200 mg
Injectable; Subcutaneous; Amoxicillin Sodium 500 mg; Clavulanic Acid / Clavulanate Potassium 50 mg
Tablet, Chewable; Oral; Amoxicillin Trihydrate 125 mg; Clavulanic Acid / Clavulanate Potassium 31.25 mg
Tablet, Chewable; Oral; Amoxicillin Trihydrate 200 mg; Clavulanic Acid / Clavulanate Potassium 28.5 mg
Tablet, Chewable; Oral; Amoxicillin Trihydrate 250 mg; Clavulanic Acid / Clavulanate Potassium 62.5 mg
Tablet, Chewable; Oral; Amoxicillin Trihydrate 400 mg; Clavulanic Acid / Clavulanate Potassium 57 mg
Tablet, Dispersible; Oral; Amoxicillin Trihydrate 500 mg; Clavulanic Acid / Clavulanate Potassium 125 mg
Tablet, Film-Coated; Oral; Amoxicillin Trihydrate 500 mg; Clavulanic Acid / Clavulanate Potassium 125 mg
Tablet, Film-Coated; Oral; Amoxicillin Trihydrate 875 mg; Clavulanic Acid / Clavulanate Potassium 125 mg
Tablet; Oral; Amoxicillin Trihydrate 250 mg; Clavulanic Acid / Clavulanate Potassium 125 mg
Tablet; Oral; Amoxicillin Trihydrate 500 mg; Clavulanic Acid / Clavulanate Potassium 125 mg
Augmentin 1 gr - 14 Tablets	$ 31.20
Augmentin 228mg/5mg 70 ml - 1 Syrup	$ 17.70
Augmentin 625 mg - 14 Tablets	$ 31.20
Augmentin 457mg/5mg 35 ml - 1 Syrup	$ 17.70
Augmentin 457mg/5mg 70 ml - 1 Syrup	$ 26.00
Augmentin duo 457mg/5mg 35 ml - 1 Syrup	$ 17.70
AUGMENTIN Injection / 250mg - 50mg / 1 via units (Glaxo)	$ 0.80
AUGMENTIN Injection / 1000mg - 200mg / 1vial units (Glaxo)	$ 2.55
AUGMENTIN Capsule/ Tablet / 250mg - 125mg / 6 units (Glaxo)	$ 2.61
AUGMENTIN Capsule/ Tablet / 875mg - 125mg / 4 units (Glaxo)	$ 2.53
AUGMENTIN Capsule/ Tablet / 500mg - 125mg / 6 units (Glaxo)	$ 2.77
AUGMENTIN Injection / 500mg - 100mg / 1vial units (Glaxo)	$ 1.45
AUGMENTIN Liquid / 875mg - 125mg / 30ml units (Glaxo)	$ 1.25
Augmentin Amoxicillin 200mg, ClavulanicAcid 28.75mg/5mL D -SYR / 30ml	$ 1.09
Augmentin Amoxicillin 1g, ClavulanicAcid 200mg VIAL / 1	$ 2.15
Augmentin Amoxicillin 250mg, ClavulanicAcid 50mg VIAL / 1	$ 0.65
Augmentin Amoxicillin 500mg, ClavulnateK 100mg VIAL / 1	$ 1.12
Augmentin 20's
Augmentin ES 50 mL
Augmentin ES 100 mL
Augmentin SR 7 x 4's
Augmentin 10's	$ 92.74
Augmentin 14's	$ 34.06
Augmentin 60 mL	$ 6.80
Augmentin 70 mL	$ 8.13
Augmentin 35 mL	$ 6.56
Augmentin 30's	$ 30.90
Augmentin / vial 1's	$ 11.70
Augmentin 100 mL
Augmentin 1's
Augmentin 5 x 20's
1's	$ 2.56
30ml	$ 1.31
Augmentin 625 mg x 60's	$ 51.52
Augmentin 1 g x 14's	$ 16.25
Augmentin 60 mL x 1's	$ 4.97
Augmentin Forte 60 mL x 1's	$ 6.67
Augmentin 70 mL x 1's
Augmentin / vial 10's
Augmentin Amoxicillin 250 mg, clavulanicacid 50 mg. VIAL / 1	$ 0.80
Augmentin Amoxicillin 200 mg, clavulanicacid 28.5 mg/5 mL. DRY-SYR / 30ml	$ 1.31
Augmentin Amoxicillin 500 mg, clavulanicacid 100 mg. VIAL / 1	$ 1.45
Augmentin Amoxicillin 1 g, clavulanicacid 200 mg. VIAL / 1	$ 2.56
AUGMENTIN 1000MG/200MG INJECTION 1 vial / 10 ML injection each (Glaxo SmithKline Pharmaceuticals Ltd)	$ 1.44
AUGMENTIN 250MG/50MG INJECTION 1 vial / 10 ML injection each (Glaxo SmithKline Pharmaceuticals Ltd)	$ 0.62
AUGMENTIN -375 TABLET 1 strip / 10 tablets each (Glaxo SmithKline Pharmaceuticals Ltd)	$ 2.76
AUGMENTIN 500MG/100MG INJECTION 1 vial / 10 ML injection each (Glaxo SmithKline Pharmaceuticals Ltd)	$ 1.15
AUGMENTIN DDS 400MG/57MG SYRUP 1 bottle / 30 ML syrup each (Glaxo SmithKline Pharmaceuticals Ltd)	$ 1.30
AUGMENTIN DUO-1000 TABLET 1 strip / 10 tablets each (Glaxo SmithKline Pharmaceuticals Ltd)	$ 5.19
AUGMENTIN DUO 200 MG/28.50 MG DRY SYRUP 1 bottle / 30 ML dry syrup each (Glaxo SmithKline Pharmaceuticals Ltd)	$ 0.64
AUGMENTIN DUO-625 TABLET 1 strip / 10 tablets each (Glaxo SmithKline Pharmaceuticals Ltd)	$ 2.04
Augmentin 1.2 g inj / vial 10 x 1's (GlaxoSmithKline)
Augmentin 600 mg inj / vial 10 x 1's (GlaxoSmithKline)
Augmentin 1 g tab 14's (GlaxoSmithKline)	$ 21.00
Augmentin 625 mg tab 10's (GlaxoSmithKline)
Augmentin 625 mg tab 14's (GlaxoSmithKline)
Augmentin 156 mg/5 mL syr 60 mL x 1's (GlaxoSmithKline)
Augmentin 457 mg/5 mL susp 35 mL x 1's (GlaxoSmithKline)
Augmentin 375 mg tab 20's (GlaxoSmithKline)
AUGMENTIN dry syr 30ml (GSK)	$ 1.31
Augmentin 1 g FC tab 10's (GlaxoSmithKline)
Augmentin 1 g FC tab 14's (GlaxoSmithKline)
Augmentin 625 mg FC tab 10's (GlaxoSmithKline)
Augmentin 625 mg FC tab 14's (GlaxoSmithKline)
Augmentin 62.5 mg/mL oral drops / w/ an aluminum roll on pilfer-proof cap + plastic syringe dosing device 20 mL x 1's (GlaxoSmithKline)
Augmentin 156.25 mg/5 mL oral susp 60 mL x 1's (GlaxoSmithKline)	$ 2.99
Augmentin 228.5 mg/5 mL oral susp 70 mL x 1's (GlaxoSmithKline)	$ 4.28
Augmentin 312.5 mg/5 mL oral susp 60 mL x 1's (GlaxoSmithKline)	$ 4.81
Augmentin 457 mg/5 mL oral susp 35 mL x 1's (GlaxoSmithKline)	$ 5.43
Augmentin 457 mg/5 mL oral susp 70 mL x 1's (GlaxoSmithKline)	$ 6.96
Augmentin 375 mg tab 30's (GlaxoSmithKline)	$ 25.14
Augmentin 625 mg tab 30's (GlaxoSmithKline)	$ 30.90
Augmentin 1000 Duo Tablet (Glaxo SmithKline Pharmaceuticals Ltd)	$ 0.52
Augmentin 1000mg/200mg Injection (Glaxo SmithKline Pharmaceuticals Ltd)	$ 0.14
Augmentin 250mg/50mg Injection (Glaxo SmithKline Pharmaceuticals Ltd)	$ 0.06
Augmentin Dds 400 mg/57 mg Syrup (Glaxo SmithKline Pharmaceuticals Ltd)	$ 1.30
List of Augmentin substitutes (brand and generic names):
Augmentan Tropfen für Säuglinge (Germany)
Augmentin 1 g/125 mg (France)
Augmentin 1 g/200 mg (France)
Augmentin 1,000
Augmentin 1,2 iu (Turkey)
Augmentin 1.1g Kind (Switzerland)
Augmentin 1.2g (Switzerland)
Augmentin 1000 mg/100 mg (Austria)
Augmentin 1000 mg/200 mg (Hungary)
Augmentin 125 mg/31.25 mg/5 ml (Bulgaria, Hungary)
Augmentin 125/31 SF (United Kingdom)
Augmentin 125mg (United States)
Augmentin 125mg/5ml (Israel)
Augmentin 12h
Suspension; Oral; Amoxicillin Trihydrate 200 mg; Clavulanic Acid / Clavulanate Potassium 28.5 mg / 5 ml
Suspension; Oral; Amoxicillin Trihydrate 400 mg; Clavulanic Acid / Clavulanate Potassium 57 mg / 5 ml
Tablet; Oral; Amoxicillin Trihydrate 875 mg; Clavulanic Acid / Clavulanate Potassium 125 mg
Augmentin 1g (Israel, Switzerland)
Augmentin 2 g/200 mg (Austria, France)
Augmentin 2.2g (Switzerland)
Augmentin 228
Augmentin 250 mg/125 mg (Bulgaria, Hungary)
Augmentin 250 mg/62.5 mg/5 ml (Bulgaria, Hungary)
Augmentin 250/62 SF (United Kingdom)
Augmentin 250mg (Israel, United States)
Augmentin 250mg/5ml (Israel)
Augmentin 312 Mg
Augmentin 375
Augmentin 375 Tablet (Glaxo SmithKline Pharmaceuticals Ltd)	$ 0.28
Augmentin 375mg (United Kingdom)
Augmentin 400 mg/57 mg (Turkey)
Augmentin 400 mg/57 mg/5 m (Austria, Bulgaria)
Augmentin 400/57 (United Kingdom)
Augmentin 400mg/5ml (Israel)
Augmentin 457
Augmentin 500 mg/100 mg (Hungary)
Augmentin 500 mg/125 mg (Austria, Bulgaria, Hungary)
Augmentin 500 mg/50 mg (Austria, France)
Augmentin 500 mg/62,5 mg (France)
Augmentin 500mg (Israel)
Augmentin 550mg Kind (Switzerland)
Augmentin 625
Augmentin 625 Duo Tablet (Glaxo SmithKline Pharmaceuticals Ltd)	$ 0.21
Augmentin 625 Mg
Augmentin 625mg (Switzerland, United Kingdom)
See 15282 substitutes for Augmentin

References

1. DailyMed. "AMOXICILLIN; CLAVULANATE POTASSIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. DailyMed. "ALENDRONATE SODIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
3. PubChem. "CLAVULANIC ACID". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Augmentin are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Augmentin. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 27 here

Information checked by Dr. Sachin Kumar, MD Pharmacology